Jazz Pharmaceuticals Unveils Key ASCO 2025 Data on Cancer Treatments

Jazz Pharmaceuticals has announced its participation in the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, set to take place from May 30 to June 3, 2025, in Chicago and online. The company, in collaboration with its partners, will present seven abstracts during the event, showcasing data from clinical trials involving several of its products, including Zepzelca® (lurbinectedin), Ziihera® (zanidatamab-hrii), Vyxeos® (daunorubicin and cytarabine), and the investigational drug dordaviprone (ONC201).

One of the key presentations will focus on the Phase 3 IMforte trial, which examined the combination of Zepzelca and atezolizumab (Tecentriq®) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS). This data underlies Jazz’s recent supplemental New Drug Application submission to the FDA, aimed at expanding the use of Zepzelca in the treatment pathway for ES-SCLC patients.

The meeting will also see the presentation of long-term outcomes and survival data for Ziihera in a Phase 2 trial in combination with chemotherapy for patients with HER2-positive advanced or metastatic gastroesophageal adenocarcinoma. This data supports the continued development of Ziihera as a promising treatment option in this patient population, with Phase 3 results anticipated later in the year.

Another focus of Jazz’s presence at ASCO will be the efficacy and safety data from a Phase 2 trial of dordaviprone (ONC201) in both adult and pediatric patients with recurrent H3 K27M-mutant diffuse glioma. These findings highlight dordaviprone’s potential as a treatment option for this aggressive form of brain cancer, which currently lacks FDA-approved therapies.

The full abstracts for Jazz’s presentations will be accessible on May 22, 2025. Additionally, the company will host an investor webcast on June 10 to discuss the data presented at ASCO. This webcast will include insights from small cell lung cancer experts and Jazz Pharmaceuticals’ senior management.

Zepzelca is an alkylating agent that disrupts the cell cycle and potentially induces cell death by binding to DNA. Initially approved under accelerated approval by the FDA in 2020 for patients with metastatic small cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy, Zepzelca’s approval was based on overall response rate and duration of response.

Ziihera is a bispecific HER2-directed antibody, targeting two extracellular sites on HER2, leading to reduced HER2 expression on tumor cells and inducing various forms of tumor cell cytotoxicity. In the U.S., it is approved for previously treated HER2-positive biliary tract cancer, with ongoing development for other HER2-expressing solid tumors.

Vyxeos, a liposomal formulation combining daunorubicin and cytarabine, is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes in patients aged one year and older.

Dordaviprone is a first-in-class small molecule that targets specific mitochondrial and receptor pathways, with ongoing development for treating H3 K27M-mutant gliomas.

Jazz Pharmaceuticals, headquartered in Dublin, Ireland, is a biopharmaceutical company focused on developing therapies for serious diseases, including central nervous system disorders and cancer. The company’s research and development efforts aim to deliver innovative treatments that address unmet patient needs globally.